Direct Customer Solution Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Direct Customer Solution Pharmaceutical Import Records from India — 3 Products, $1.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Direct Customer Solution — Pharmaceutical Importer Profile (2026) | 3 Products, $1.8M Trade | TransData Nexus

Direct Customer Solution

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $1.8M Total Trade · DGFT Verified

Direct Customer Solution is a pharmaceutical importer based in United States with a total trade value of $1.8M across 3 products in 3 therapeutic categories. Based on 57 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Direct Customer Solution sources from 18 verified Indian suppliers, with Orbion Pharmaceuticals Private Limited accounting for 40.7% of imports.

Direct Customer Solution — Import Portfolio & Supplier Network

Direct Customer Solution import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Direct Customer Solution?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Orbion Pharmaceuticals Private Limited	$8.9M	351	40.7%
Rubicon Research Private Limited	$4.9M	206	22.3%
Steril-gene Life Sciences Private Limited

What Formulations Does Direct Customer Solution Import?

Formulation	Value	Ships
Progesterone 200 MG capsules - progesterone soft gelatin capsules 200MG ( units: 1 x 100's)	$700.0K	14
Progesterone 100 MG capsules - progesterone soft gelatin capsules 100MG ( units: 1 x 100's)	$698.3K	14
Sildenafil tablets USP 20MG 1000 s tabsper	$548.7K	19
Pregabalin	$478.0K	22
Lacosamide	$362.9K	21
Pregabalin capsulenos	$335.6K	39
Fluvoxamine maleate tablets USP 100MG uc, 100s	$331.0K	7
Fosaprepitant	$282.3K	6
(softgelatin capsules)-vitamin d 1.25 mg50000 USP CAPS 100/bt ergocalciferol capsules USP 1250 MCG material	$250.0K	5
Dicyclomine hcl tablets USP 20MG hdpe 1000's, Pack: 1000	$226.5K	6
Carvedilol TAB USP 25MG 1000's batch no.	$200.0K	4
Tramadol hcl tablets USP 100MG 100s tabs per	$200.0K	4
Loperamide hcl capsules USP 2MG hdpe 100s, Pack: 100	$200.0K	4
Cevimeline hcl capsules USP 30MG Pack:100 CAPS	$200.0K	4
Progesterone soft gelatin capsules 200MG(ndc no:69452-234-20) (units 1x 100s)	$198.6K	5

Direct Customer Solution imports 402 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Tramadol	Analgesics & Antipyretics	$1.1M	23	0.3%	11
2	Clonazepam	CNS & Psychiatric	$317.1K	28	0.2%	11
3	Amiodarone	Cardiovascular	$300.0K	6	0.4%	17

Direct Customer Solution imports 3 pharmaceutical products across 3 categories into United States totaling $1.8M.

Direct Customer Solution — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Direct Customer Solutions (DCS) is a privately held, family-owned third-party logistics (3PL) provider specializing in the pharmaceutical and healthcare sectors. Established in 2017 and headquartered in Bells, Tennessee, DCS offers a comprehensive suite of services, including supply chain management, cold chain logistics, specialty drug handling, and pharmaceutical warehousing. Their mission is to deliver white-glove, end-to-end logistics solutions that ensure the safe, compliant, and transparent movement of medical products, empowering pharmaceutical manufacturers, pharmacies, and hospitals to focus on patient care while managing the complexities of the supply chain.

DCS's services are tailored to meet the unique demands of the pharmaceutical industry, emphasizing compliance and efficiency at every step. Their state-of-the-art facilities utilize advanced technologies, such as the only pharmaceutical vertical robotics system in the country, to minimize human interaction and improve product integrity and data transparency. By offering direct distribution models, DCS enables pharmaceutical manufacturers to self-distribute their medications directly to dispensing sites, including specialty pharmacies, hospitals, and clinics, thereby eliminating traditional wholesaler chargebacks and enhancing operational efficiency.

2Distribution Network

DCS operates a centralized distribution network from its facility in Bells, Tennessee, strategically located to serve the continental United States. The facility is equipped with advanced logistics capabilities, including a high-bay storage system and validated cold-chain solutions, ensuring the secure and compliant storage and distribution of pharmaceutical products. While the company primarily focuses on domestic distribution, its robust infrastructure and compliance with regulatory standards position it to potentially expand its geographic coverage beyond the United States in the future.

3Industry Role

In the United States pharmaceutical supply chain, DCS functions as a third-party logistics provider rather than a traditional wholesaler or distributor. By offering direct distribution models, DCS enables pharmaceutical manufacturers to self-distribute their medications directly to dispensing sites, including specialty pharmacies, hospitals, and clinics. This approach eliminates traditional wholesaler chargebacks and enhances operational efficiency, positioning DCS as a strategic partner in the pharmaceutical logistics sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Direct Customer Solution

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

DCS's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a select group of Indian suppliers. Notably, ORBION PHARMACEUTICALS PRIVATE LIMITED accounts for 40.7% of the total import value, followed by RUBICON RESEARCH PRIVATE LIMITED at 22.3%, and STERIL-GENE LIFE SCIENCES PRIVATE LIMITED at 12.3%. This concentrated sourcing approach may present risks related to supply chain disruptions, such as those arising from regulatory actions or operational challenges faced by these key suppliers. However, it also suggests a strategic choice by DCS to establish strong, reliable partnerships with select suppliers to ensure product quality and consistency.

The shipment data indicates a stable relationship with these suppliers, as evidenced by the consistent volume of imports over the years. For instance, ORBION PHARMACEUTICALS PRIVATE LIMITED has been a consistent supplier, contributing significantly to DCS's import portfolio. This stability may mitigate potential risks associated with sourcing concentration, provided that DCS maintains effective risk management strategies and continues to monitor the performance and compliance of its key suppliers.

2Supply Chain Resilience

DCS's supply chain resilience is bolstered by its diversified portfolio of 402 unique pharmaceutical formulations imported from India. This diversity reduces dependency on any single product or supplier, enhancing the company's ability to adapt to market changes and potential disruptions. Additionally, DCS's strategic partnerships with multiple Indian suppliers, including ORBION PHARMACEUTICALS PRIVATE LIMITED, RUBICON RESEARCH PRIVATE LIMITED, and STERIL-GENE LIFE SCIENCES PRIVATE LIMITED, provide alternative sourcing options, further strengthening supply chain resilience. The company's compliance with regulatory standards and its investment in advanced logistics infrastructure, such as validated cold-chain solutions, also contribute to the robustness of its supply chain operations.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA ensures that imported drugs meet the same standards for quality, safety, and effectiveness as those manufactured domestically. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices. Additionally, the Drug Enforcement Administration (DEA) regulates controlled substances, ensuring that their importation complies with federal law.

The marketing authorization pathway for Indian generics involves obtaining approval from the FDA through the Abbreviated New Drug Application (ANDA) process. This process requires demonstrating that the generic product is bioequivalent to the reference listed drug and complies with FDA's current good manufacturing practice (CGMP) regulations. Once approved, the product is listed in the FDA's Orange Book, allowing for legal importation and distribution within the United States.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Importers must ensure that their products are FDA-approved and comply with all applicable regulations. The FDA requires that foreign manufacturers register their establishments and list their drugs with the agency. Additionally, products must be manufactured in facilities that adhere to CGMP standards, which are recognized by the FDA. For Indian manufacturers, compliance with WHO GMP or PIC/S standards is typically acceptable, provided the manufacturing facility is listed in the FDA's Drug Establishments Current Registration Site.

Direct Customer Solution — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

DCS's product category focus on Analgesics & Antipyretics (65.1%), CNS & Psychiatric (17.9%), and Cardiovascular (17.0%) reflects a strategic alignment with prevalent therapeutic needs in the United States. The significant importation of Tramadol, Clonazepam, and Amiodarone indicates a targeted approach to sourcing medications that address common and critical health conditions. Market demand for these products is driven by factors such as the aging population, increasing prevalence of chronic diseases, and the need for effective pain management and psychiatric care.

The concentration of imports in these therapeutic areas suggests that DCS is positioning itself to meet the substantial demand for these medications, potentially enhancing its market share and establishing strong partnerships with healthcare providers and patients.

2Sourcing Profile

DCS's sourcing strategy emphasizes the importation of generic drugs, focusing on formulations that are bioequivalent to branded counterparts. This approach allows DCS to offer cost-effective alternatives while maintaining product quality and efficacy. India's robust pharmaceutical manufacturing sector, with its adherence to international quality standards, makes it a strategic sourcing partner for DCS. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, aligns with its commitment to delivering ready-to-use products that meet the needs of healthcare providers and patients.

Frequently Asked Questions — Direct Customer Solution

What products does Direct Customer Solution import from India?

Direct Customer Solution imports 3 pharmaceutical products across 3 categories. Top imports: Tramadol ($1.1M), Clonazepam ($317.1K), Amiodarone ($300.0K).

Who supplies pharmaceuticals to Direct Customer Solution from India?

Direct Customer Solution sources from 18 verified Indian suppliers. The primary supplier is Orbion Pharmaceuticals Private Limited (40.7% of imports, $8.9M).

What is Direct Customer Solution's total pharmaceutical import value?

Direct Customer Solution's total pharmaceutical import value from India is $1.8M, based on 57 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Direct Customer Solution focus on?

Direct Customer Solution imports across 3 categories. The largest: Analgesics & Antipyretics (65.1%), CNS & Psychiatric (17.9%), Cardiovascular (17.0%).

Get Full Direct Customer Solution Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Direct Customer Solution

Direct Customer Solution — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Direct Customer Solution?

What Formulations Does Direct Customer Solution Import?

What Products Does Direct Customer Solution Import?

Top Products by Import Value

Direct Customer Solution Therapeutic Categories — 3 Specializations